Page last updated: 2024-11-02

pimobendan and Heart Failure

pimobendan has been researched along with Heart Failure in 105 studies

pimobendan: produces arterial & venous dilatation in dogs; structure given in first source

Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.

Research Excerpts

ExcerptRelevanceReference
"The benefits of pimobendan in the treatment of congestive heart failure (CHF) in cats with hypertrophic cardiomyopathy (HCM) have not been evaluated prospectively."9.41Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. ( Glaus, T; Lehmkuhl, L; Loureiro, J; Luis Fuentes, V; MacGregor, J; Mohren, N; Rush, JE; Sayer, MP; Schober, KE; Summerfield, NJ; Wess, G; Wright, K, 2021)
"A fixed-dose combination tablet of benazepril and pimobendan (Fortekor Plus; Elanco Animal Health) was tested in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD) in a three-arm, masked, randomized, non-inferiority clinical trial in Japan."9.27Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial. ( Forster, S; Hirakawa, A; King, JN; Otaki, H; Sakakibara, N; Seewald, W; Sonobe, J, 2018)
"Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD)."9.22Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2016)
"No significant difference between pimobendan and placebo was found on incidence of supraventricular or ventricular arrhythmia."9.20Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration. ( Griffiths, LG; Kass, PH; Lake-Bakaar, GA; Singh, MK, 2015)
"To evaluate the clinical efficacy and safety of pimobendan by comparing it with ramipril over a six-month period in dogs with mild to moderate heart failure (HF) caused by myxomatous mitral valve disease (MMVD)."9.11Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease. ( Corcoran, BM; Dukes-McEwan, J; French, AT; Lee, AJ; Smith, PJ; Smith, SG; Swift, ST; Van Israël, N, 2005)
"The long-term beneficial effects of pimobendan in the treatment of chronic heart failure (CHF) have not been established, so the present trial compared pimobendan (1."9.10Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). ( , 2002)
"To evaluate the effects of the addition of pimobendan to an optimal basic regimen on plasma levels of neurohumoral factors in patients with non-ischemic, moderate heart failure during 2-year follow-up."9.09Effects of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure. ( Komamura, K; Kubo, T; Nishikimi, T; Sasaki, T, 1999)
"Pimobendan improves exercise capacity in patients with chronic heart failure who are also on conventional treatment."9.08Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. ( Dumont, JM; Heinrich-Nols, J; Hjalmarsson, AC; Just, H; La Framboise, D; Lubsen, J; Remme, WJ; Seed, P, 1996)
"The results of Japanese studies on the clinical efficacy and safety of pimobendan in the treatment of heart failure are summarized in this paper."9.08Clinical efficacy and safety of pimobendan in treatment of heart failure--experience in Japan. ( Kato, K, 1997)
"The effects of pimobendan (UD-CG 115) on hemodynamics and exercise capacity after acute (single dose) and chronic (6 month) oral treatment, as well as acute treatment after 6 months were investigated in 67 patients with chronic heart failure of NYHA classes II or III, which had persisted in spite of treatment with diuretics and digitalis."9.07[Acute and long-term effects of pimobendan (UD-CG 115) in NYHA II and III heart failure. Results of a randomized multicenter double-blind study]. ( Assmann, I; Duck, HG; Fiehring, H; Höfs, T; Kassel, P; Morgan, P; Nehmiz, G; Schmidt, PK, 1991)
"Acute hemodynamics of pimobendan were compared to captopril in a crossover trial in patients with chronic heart failure (NYHA II-III)."9.07Acute hemodynamics of pimobendan in chronic heart failure. A comparative crossover study of captopril and pimobendan. ( Aizaki, T; Hanawa, H; Izumi, T; Kodama, M; Kuwano, H; Shibata, A; Suzuki, M; Takahashi, M; Tsuda, T; Uchiyama, H, 1992)
"These data demonstrate that pimobendan significantly increases exercise duration, peak VO2, and quality of life in patients with heart failure."9.07Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. ( Bourge, R; Brodsky, M; Brozena, S; Cobb, F; Gollub, S; Jessup, M; Kirlin, P; Kubo, SH; Rahko, P; Shanes, J, 1992)
"To determine the reliability and validity of a patient outcome questionnaire for chronic heart failure, a randomized, double-blind, placebo-controlled, 3-month trial of pimobendan, an investigational medication with inotropic and vasodilator activities, was performed."9.07Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. ( Cohn, JN; Rector, TS, 1992)
"In view of growing scepticism as to the efficacy and safety of agents with predominant phosphodiesterase inhibiting properties in heart failure, the clinical efficacy and safety of pimobendan, a calcium-sensitizing and partially phosphodiesterase-inhibiting compound, was compared with enalapril in 242 patients with mild to moderate heart failure (NYHA classification II-III) despite diuretics and digitalis, and abnormal haemodynamics at baseline."9.07Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group. ( Baiker, W; Baumann, G; Frick, MH; Haehl, M; Krayenbühl, HP; Nehmiz, G; Remme, WJ, 1994)
"In contrast to cyclic AMP-dependent positive inotropes, the calcium-sensitizer and partial phosphodiesterase (PDE) inhibitor pimobendan may induce beneficial effects in heart failure."9.07Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. ( Bartels, GL; de Leeuw, PW; Krauss, XH; Kruijssen, DA; Remme, WJ; Storm, CJ; van Hoogenhuyze, DC, 1994)
"The long-term efficacy of the positive inotropic and vasodilator drug, pimobendan, was assessed in 21 patients suffering from symptomatic heart failure."9.07Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. ( Asanoi, H; Ejiri, M; Horikoshi, I; Kihara, Y; Sasayama, S; Terada, Y; Yokawa, S; Yoshida, S, 1994)
"In 25 patients whose chronic congestive heart failure (CHF) had recently worsened to New York Heart Association class IV, pimobendan (5 to 20 mg/day) was added to maximum conventional therapy consisting of digoxin, diuretics, angiotensin-converting enzyme inhibitors, coumadin derivatives to prevent thromboembolic complications, and amiodarone to suppress serious ventricular rhythm disturbances."9.07Intractable heart failure despite angiotensin-converting enzyme inhibitors, digoxin, and diuretics: long-term effectiveness of add-on therapy with pimobendan. ( Hagemeijer, F, 1991)
" We compared the effects of two doses (5 and 10 mg) of oral pimobendane (UD-CG 115) on haemodynamics in eight patients suffering from chronic congestive heart failure."9.06Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses. ( Bernard, R; Dresse, A; Goethals, H; Liebens, I; Renard, M; Walter, M, 1988)
"Pimobendan is an oral inodilator compound available in many countries for use in canine heart failure."8.82Use of pimobendan in the management of heart failure. ( Fuentes, VL, 2004)
"The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD)."7.85Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure. ( Chimura, S; Endo, M; Harada, K; Hirakawa, A; Maetani, S; Mizukoshi, T; Mizuno, M; Mizuno, T; Sawada, T; Shinoda, A; Takahashi, A; Takeuchi, J; Takusagawa, Y; Uchida, S; Uechi, M; Yamano, S, 2017)
"We evaluated the effect of pimobendan, a positive inotropic agent, in elderly patients with frequent readmission as a result of heart failure despite conventional therapy."7.80Effect of pimobendan in addition to standard therapy for heart failure on prevention of readmission in elderly patients with severe chronic heart failure. ( Arakawa, S; Hayano, M; Kawano, H; Maemura, K; Matsumoto, Y; Nakatomi, D; Satoh, O; Yamasa, T, 2014)
"To assess survival time and adverse events related to the administration of pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM)."7.80Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. ( Ames, MK; Atkins, CE; DeFrancesco, TC; Hodge, TE; Keene, BW; Meurs, KM; Reina-Doreste, Y; Stern, JA; Tou, SP, 2014)
"27 client-owned cats (16 male and 11 female) with heart failure, treated with pimobendan (mean ± SD dosage, 0."7.78Effect of oral administration of pimobendan in cats with heart failure. ( Achen, SE; Boggess, MM; Drourr, L; Fries, RC; Gordon, SG; Hariu, CD; Miller, MW; Roland, RM; Saunders, AB; Winter, RL, 2012)
" Using 6 conscious dogs with tachycardia-induced heart failure, the FFR was examined before and after administration of dobutamine (6 microg/kg/min) or pimobendan (0."7.71Disparate force-frequency effects of pimobendan and dobutamine in conscious dogs with tachycardia-induced cardiomyopathy. ( Asanoi, H; Inoue, H; Ishizaka, S; Joho, S; Kameyama, T, 2002)
"Pharmacokinetics and pharmacodynamics of pimobendan were studied in eight patients with dilated cardiomyopathy and chronic congestive heart failure after single dosing and after 2-week repeated dosing of 5 mg racemic pimobendan."7.69Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing. ( Chu, KM; Hu, OY; Shieh, SM, 1995)
"We studied the effects of oral administration of pimobendane on hemodynamics, blood gas levels, the renin-angiotensin system, and plasma catecholamines in 11 patients who were affected by severe chronic congestive heart failure."7.67Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent. ( Bernard, R; Dresse, A; Liebens, I; Renard, M; Walter, M, 1988)
"Pimobendan (UD-CG 115 BS) was administered orally to 23 patients with congestive heart failure (functional class IV) caused by coronary artery disease (11 patients) or idiopathic dilated cardiomyopathy (12)."7.67Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. ( Brand, HJ; Hagemeijer, F; van Mechelen, R, 1989)
"Pimobendan (10 mg on day 1, then 5 mg twice daily for 28 days) was administered orally to nine patients in class III-IV stable congestive heart failure."7.67Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing. ( Brand, HJ; Hagemeijer, F; Roth, W, 1989)
"The acute systemic hemodynamic effects of the calcium antagonist nisoldipine and the pyridazinone-derivative pimobendan, a phosphodiesterase inhibitor with vasodilating as well as positive inotropic properties, were studied in conscious pigs with chronic heart failure."7.67Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure. ( Duncker, DJ; Roelandt, JR; van der Giessen, WJ; van Woerkens, LJ; Verdouw, PD, 1989)
"Pimobendan was administered orally (10 mg single dose on day 1, then 5 mg twice daily for 4 weeks) to nine patients with chronic heart failure undergoing hemodynamic monitoring."7.67Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure. ( Brand, HJ; Hagemeijer, F; Roth, W, 1989)
"Pimobendan is a positive inotropic agent with additional calcium-sensitizing effects of the phosphodiesterase III-inhibitor group."6.67[Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure]. ( Bergler-Klein, J; Globits, S; Glogar, D; Mayr, H; Porenta, G; Sochor, H; Stefenelli, T, 1992)
"Pimobendan is a benzimidazole-pyridazinone derivative with calcium-sensitizing properties that increases myocardial contractile force without increasing intracellular calcium."6.40Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. ( Kubo, SH, 1997)
"Pimobendan is a novel cardiotonic vasodilator (inodilator) which derives its inotropic activity from a combination of phosphodiesterase III inhibition and sensitisation of myocardial contractile proteins to calcium."6.39Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure. ( Brogden, RN; Fitton, A, 1994)
"In patients with chronic congestive heart failure, pimobendan produces a dose-dependent and prolonged decrease in pulmonary capillary wedge pressure and an increase in cardiac output."6.38Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. ( Hagemeijer, F, 1993)
"A knock-in mouse model of human genetic dilated cardiomyopathy, which shows a clear transition from compensatory to end-stage HF at a fixed time during growth, was used to evaluate the efficacy of pimobendan and explore the underlying molecular and cellular mechanisms."5.42Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. ( Arioka, M; Kurebayashi, N; Li, L; Morimoto, S; Murayama, T; Nonaka, M; Sasaguri, T; Takahashi-Yanaga, F; Wang, YY; Yoshihara, T, 2015)
"The benefits of pimobendan in the treatment of congestive heart failure (CHF) in cats with hypertrophic cardiomyopathy (HCM) have not been evaluated prospectively."5.41Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study. ( Glaus, T; Lehmkuhl, L; Loureiro, J; Luis Fuentes, V; MacGregor, J; Mohren, N; Rush, JE; Sayer, MP; Schober, KE; Summerfield, NJ; Wess, G; Wright, K, 2021)
"Heart failure was induced in 20 dogs, to which pimobendan and two different doses of SCH00013 were administered orally to 15 dogs for 3 weeks, and the remaining 5 dogs served as the control."5.40Comparative evaluation of calcium-sensitizing agents, pimobendan and SCH00013, on the myocardial function of canine pacing-induced model of heart failure. ( Fukayama, T; Fukushima, R; Hamabe, L; Kawamura, K; Kim, SM; Shimizu, M; Tanaka, R; Yoshiyuki, R, 2014)
"Triple therapy (TT) consisting of furosemide, pimobendan, and an angiotensin-converting enzyme inhibitor (ACEI) frequently is recommended for the treatment of congestive heart failure (CHF) attributable to myxomatous mitral valve disease (MMVD)."5.34Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial. ( Bauer, A; Gaugele, J; Glaus, T; Holler, P; Keller, L; Killich, M; Kresken, JG; Küchenhof, H; Simak, J; Wendt, R; Wess, G, 2020)
"Heart failure was induced by rapid ventricular pacing in 6 dogs instrumented with a micromanometer and a conductance catheter."5.29Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure. ( Asanoi, H; Ishise, H; Ishizaka, S; Kameyama, T; Sasayama, S, 1994)
"Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly have not been described."5.27Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Schummer, C; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2018)
"A fixed-dose combination tablet of benazepril and pimobendan (Fortekor Plus; Elanco Animal Health) was tested in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD) in a three-arm, masked, randomized, non-inferiority clinical trial in Japan."5.27Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial. ( Forster, S; Hirakawa, A; King, JN; Otaki, H; Sakakibara, N; Seewald, W; Sonobe, J, 2018)
"Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD)."5.22Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. ( Abbott, JA; Barrett, KA; Bomassi, E; Bonagura, J; Boswood, A; Church, WM; Deinert, M; Estrada, AH; Fernandez Del Palacio, MJ; Fox, PR; Fujii, Y; Gordon, SG; Häggström, J; Jaudon, JP; Keene, BW; Kresken, JG; Ljungvall, I; Luethy, MW; MacDonald, KA; Menaut, P; Moise, NS; O'Sullivan, ML; Oyama, MA; Patteson, M; Rosenthal, SL; Rush, J; Sanderson, K; Santilli, RA; Saunders, AB; Smith, S; Spier, A; Stepien, RL; Szatmári, V; Tidholm, A; Uechi, M; Watson, P; Wess, G; Woolley, R, 2016)
"No significant difference between pimobendan and placebo was found on incidence of supraventricular or ventricular arrhythmia."5.20Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration. ( Griffiths, LG; Kass, PH; Lake-Bakaar, GA; Singh, MK, 2015)
"To evaluate the clinical efficacy and safety of pimobendan by comparing it with ramipril over a six-month period in dogs with mild to moderate heart failure (HF) caused by myxomatous mitral valve disease (MMVD)."5.11Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease. ( Corcoran, BM; Dukes-McEwan, J; French, AT; Lee, AJ; Smith, PJ; Smith, SG; Swift, ST; Van Israël, N, 2005)
"The long-term beneficial effects of pimobendan in the treatment of chronic heart failure (CHF) have not been established, so the present trial compared pimobendan (1."5.10Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study). ( , 2002)
"To evaluate the effects of the addition of pimobendan to an optimal basic regimen on plasma levels of neurohumoral factors in patients with non-ischemic, moderate heart failure during 2-year follow-up."5.09Effects of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure. ( Komamura, K; Kubo, T; Nishikimi, T; Sasaki, T, 1999)
"Pimobendan improves exercise capacity in patients with chronic heart failure who are also on conventional treatment."5.08Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. ( Dumont, JM; Heinrich-Nols, J; Hjalmarsson, AC; Just, H; La Framboise, D; Lubsen, J; Remme, WJ; Seed, P, 1996)
"The results of Japanese studies on the clinical efficacy and safety of pimobendan in the treatment of heart failure are summarized in this paper."5.08Clinical efficacy and safety of pimobendan in treatment of heart failure--experience in Japan. ( Kato, K, 1997)
"The effects of pimobendan (UD-CG 115) on hemodynamics and exercise capacity after acute (single dose) and chronic (6 month) oral treatment, as well as acute treatment after 6 months were investigated in 67 patients with chronic heart failure of NYHA classes II or III, which had persisted in spite of treatment with diuretics and digitalis."5.07[Acute and long-term effects of pimobendan (UD-CG 115) in NYHA II and III heart failure. Results of a randomized multicenter double-blind study]. ( Assmann, I; Duck, HG; Fiehring, H; Höfs, T; Kassel, P; Morgan, P; Nehmiz, G; Schmidt, PK, 1991)
"In 25 patients whose chronic congestive heart failure (CHF) had recently worsened to New York Heart Association class IV, pimobendan (5 to 20 mg/day) was added to maximum conventional therapy consisting of digoxin, diuretics, angiotensin-converting enzyme inhibitors, coumadin derivatives to prevent thromboembolic complications, and amiodarone to suppress serious ventricular rhythm disturbances."5.07Intractable heart failure despite angiotensin-converting enzyme inhibitors, digoxin, and diuretics: long-term effectiveness of add-on therapy with pimobendan. ( Hagemeijer, F, 1991)
"In view of growing scepticism as to the efficacy and safety of agents with predominant phosphodiesterase inhibiting properties in heart failure, the clinical efficacy and safety of pimobendan, a calcium-sensitizing and partially phosphodiesterase-inhibiting compound, was compared with enalapril in 242 patients with mild to moderate heart failure (NYHA classification II-III) despite diuretics and digitalis, and abnormal haemodynamics at baseline."5.07Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group. ( Baiker, W; Baumann, G; Frick, MH; Haehl, M; Krayenbühl, HP; Nehmiz, G; Remme, WJ, 1994)
"Twenty-four patients (one female, 23 male) with mild to moderate heart failure were randomly and double-blindly assigned to an oral treatment with 5 mg enalapril twice daily or 5 mg pimobendan (UDCG 115) twice daily."5.07Comparison of hormonal and haemodynamic changes after long-term oral therapy with pimobendan or enalapril--a double-blind randomized study. ( Bleifeld, W; Erlemeier, HH; Kupper, W, 1991)
"In contrast to cyclic AMP-dependent positive inotropes, the calcium-sensitizer and partial phosphodiesterase (PDE) inhibitor pimobendan may induce beneficial effects in heart failure."5.07Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. ( Bartels, GL; de Leeuw, PW; Krauss, XH; Kruijssen, DA; Remme, WJ; Storm, CJ; van Hoogenhuyze, DC, 1994)
"To determine the reliability and validity of a patient outcome questionnaire for chronic heart failure, a randomized, double-blind, placebo-controlled, 3-month trial of pimobendan, an investigational medication with inotropic and vasodilator activities, was performed."5.07Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. ( Cohn, JN; Rector, TS, 1992)
"The long-term efficacy of the positive inotropic and vasodilator drug, pimobendan, was assessed in 21 patients suffering from symptomatic heart failure."5.07Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure. ( Asanoi, H; Ejiri, M; Horikoshi, I; Kihara, Y; Sasayama, S; Terada, Y; Yokawa, S; Yoshida, S, 1994)
"These data demonstrate that pimobendan significantly increases exercise duration, peak VO2, and quality of life in patients with heart failure."5.07Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. ( Bourge, R; Brodsky, M; Brozena, S; Cobb, F; Gollub, S; Jessup, M; Kirlin, P; Kubo, SH; Rahko, P; Shanes, J, 1992)
"Acute hemodynamics of pimobendan were compared to captopril in a crossover trial in patients with chronic heart failure (NYHA II-III)."5.07Acute hemodynamics of pimobendan in chronic heart failure. A comparative crossover study of captopril and pimobendan. ( Aizaki, T; Hanawa, H; Izumi, T; Kodama, M; Kuwano, H; Shibata, A; Suzuki, M; Takahashi, M; Tsuda, T; Uchiyama, H, 1992)
" We compared the effects of two doses (5 and 10 mg) of oral pimobendane (UD-CG 115) on haemodynamics in eight patients suffering from chronic congestive heart failure."5.06Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses. ( Bernard, R; Dresse, A; Goethals, H; Liebens, I; Renard, M; Walter, M, 1988)
"Pimobendan is approved for use in dogs for the treatment of congestive heart failure (CHF) secondary to chronic valvular heart disease (CVHD) and dilated cardiomyopathy (DCM)."4.88A review of the pharmacology and clinical uses of pimobendan. ( Boyle, KL; Leech, E, 2012)
"Pimobendan is an oral inodilator compound available in many countries for use in canine heart failure."4.82Use of pimobendan in the management of heart failure. ( Fuentes, VL, 2004)
"Pimobendan is frequently used off-label for treatments of cats with congestive heart failure (CHF)."3.96Retrospective evaluation of the safety and tolerability of pimobendan in cats with obstructive vs nonobstructive cardiomyopathy. ( DeFrancesco, TC; Keene, BW; Kussin, EZ; Tou, SP; Tropf, MA; Ward, JL, 2020)
"For study purposes, advanced heart failure was defined as recurrence of congestive heart failure signs despite receiving the initially prescribed dose of pimobendan, angiotensin-converting-enzyme inhibitor (ACEI), and furosemide >4 mg/kg/day."3.88Clinical findings and survival time in dogs with advanced heart failure. ( Beaumier, A; Freeman, LM; Rush, JE; Yang, VK, 2018)
"The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD)."3.85Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure. ( Chimura, S; Endo, M; Harada, K; Hirakawa, A; Maetani, S; Mizukoshi, T; Mizuno, M; Mizuno, T; Sawada, T; Shinoda, A; Takahashi, A; Takeuchi, J; Takusagawa, Y; Uchida, S; Uechi, M; Yamano, S, 2017)
"To assess survival time and adverse events related to the administration of pimobendan to cats with congestive heart failure (CHF) secondary to hypertrophic cardiomyopathy (HCM) or hypertrophic obstructive cardiomyopathy (HOCM)."3.80Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. ( Ames, MK; Atkins, CE; DeFrancesco, TC; Hodge, TE; Keene, BW; Meurs, KM; Reina-Doreste, Y; Stern, JA; Tou, SP, 2014)
" The patient was treated for congestive heart failure because of dilated cardiomyopathy with furosemide, enalapril, pimobendan and l-carnitine."3.80Diagnosis and treatment of congestive heart failure secondary to dilated cardiomyopathy in a hedgehog. ( Delk, KW; Eshar, D; Garcia, E; Harkin, K, 2014)
"We evaluated the effect of pimobendan, a positive inotropic agent, in elderly patients with frequent readmission as a result of heart failure despite conventional therapy."3.80Effect of pimobendan in addition to standard therapy for heart failure on prevention of readmission in elderly patients with severe chronic heart failure. ( Arakawa, S; Hayano, M; Kawano, H; Maemura, K; Matsumoto, Y; Nakatomi, D; Satoh, O; Yamasa, T, 2014)
"27 client-owned cats (16 male and 11 female) with heart failure, treated with pimobendan (mean ± SD dosage, 0."3.78Effect of oral administration of pimobendan in cats with heart failure. ( Achen, SE; Boggess, MM; Drourr, L; Fries, RC; Gordon, SG; Hariu, CD; Miller, MW; Roland, RM; Saunders, AB; Winter, RL, 2012)
"This retrospective study reports the survival time [onset of congestive heart failure (CHF) to death from any cause] of 21 dogs with mitral regurgitation (MR) and CHF treated with a combination of furosemide, angiotensin-converting enzyme inhibitor (ACEI, benazepril, or enalapril), pimobendan, spironolactone, and amlodipine."3.77Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases. ( de Madron, E; King, JN; Strehlau, G; White, RV, 2011)
"To describe the therapeutic use of pimobendan in cats, describe the patient population to which it was administered, document potential side effects and report the clinical course following administration of pimobendan in conjunction with standard heart failure therapy."3.77Use of pimobendan in 170 cats (2006-2010). ( Aronow, N; Cunningham, SM; Hall, DJ; Laste, NJ; Macgregor, JM; Malakoff, RL; Price, LL; Rush, JE; Williams, J, 2011)
" Using 6 conscious dogs with tachycardia-induced heart failure, the FFR was examined before and after administration of dobutamine (6 microg/kg/min) or pimobendan (0."3.71Disparate force-frequency effects of pimobendan and dobutamine in conscious dogs with tachycardia-induced cardiomyopathy. ( Asanoi, H; Inoue, H; Ishizaka, S; Joho, S; Kameyama, T, 2002)
"Pharmacokinetics and pharmacodynamics of pimobendan were studied in eight patients with dilated cardiomyopathy and chronic congestive heart failure after single dosing and after 2-week repeated dosing of 5 mg racemic pimobendan."3.69Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing. ( Chu, KM; Hu, OY; Shieh, SM, 1995)
"The acute systemic hemodynamic effects of the calcium antagonist nisoldipine and the pyridazinone-derivative pimobendan, a phosphodiesterase inhibitor with vasodilating as well as positive inotropic properties, were studied in conscious pigs with chronic heart failure."3.67Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure. ( Duncker, DJ; Roelandt, JR; van der Giessen, WJ; van Woerkens, LJ; Verdouw, PD, 1989)
"Pimobendan was administered orally (10 mg single dose on day 1, then 5 mg twice daily for 4 weeks) to nine patients with chronic heart failure undergoing hemodynamic monitoring."3.67Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure. ( Brand, HJ; Hagemeijer, F; Roth, W, 1989)
"Pimobendan (UD-CG 115 BS) was administered orally to 23 patients with congestive heart failure (functional class IV) caused by coronary artery disease (11 patients) or idiopathic dilated cardiomyopathy (12)."3.67Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. ( Brand, HJ; Hagemeijer, F; van Mechelen, R, 1989)
"We studied the effects of oral administration of pimobendane on hemodynamics, blood gas levels, the renin-angiotensin system, and plasma catecholamines in 11 patients who were affected by severe chronic congestive heart failure."3.67Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent. ( Bernard, R; Dresse, A; Liebens, I; Renard, M; Walter, M, 1988)
"Pimobendan (10 mg on day 1, then 5 mg twice daily for 28 days) was administered orally to nine patients in class III-IV stable congestive heart failure."3.67Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing. ( Brand, HJ; Hagemeijer, F; Roth, W, 1989)
"Pimobendan is a positive inotropic agent with additional calcium-sensitizing effects of the phosphodiesterase III-inhibitor group."2.67[Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure]. ( Bergler-Klein, J; Globits, S; Glogar, D; Mayr, H; Porenta, G; Sochor, H; Stefenelli, T, 1992)
" Classic inotropic agents (beta-adrenergic agonists and phosphodiesterase III inhibitors) can provide short-term hemodynamic benefits, but their long-term use has been correlated with poor survival rates."2.43Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure. ( Kaplinsky, EJ; Perrone, SV, 2005)
"Levosimendan is a calcium sensitizer with no major inhibition of PDE at clinically relevant doses."2.42The role of Ca++-sensitizers for the treatment of heart failure. ( Boldt, J; Kirchner, J; Lehmann, A, 2003)
"Pimobendan is a benzimidazole-pyridazinone derivative with calcium-sensitizing properties that increases myocardial contractile force without increasing intracellular calcium."2.40Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. ( Kubo, SH, 1997)
"Pimobendan is a novel cardiotonic vasodilator (inodilator) which derives its inotropic activity from a combination of phosphodiesterase III inhibition and sensitisation of myocardial contractile proteins to calcium."2.39Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure. ( Brogden, RN; Fitton, A, 1994)
"In patients with chronic congestive heart failure, pimobendan produces a dose-dependent and prolonged decrease in pulmonary capillary wedge pressure and an increase in cardiac output."2.38Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. ( Hagemeijer, F, 1993)
"In dogs with canine monocytic ehrlichiosis (CME), respiratory signs are uncommon and clinical and radiographic signs of interstitial pneumonia are poorly described."1.43Interstitial pneumonia and pulmonary hypertension associated with suspected ehrlichiosis in a dog. ( Broens, EM; Dobak, TP; Toom, ML; Valtolina, C, 2016)
"A knock-in mouse model of human genetic dilated cardiomyopathy, which shows a clear transition from compensatory to end-stage HF at a fixed time during growth, was used to evaluate the efficacy of pimobendan and explore the underlying molecular and cellular mechanisms."1.42Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. ( Arioka, M; Kurebayashi, N; Li, L; Morimoto, S; Murayama, T; Nonaka, M; Sasaguri, T; Takahashi-Yanaga, F; Wang, YY; Yoshihara, T, 2015)
"Heart failure was induced in 20 dogs, to which pimobendan and two different doses of SCH00013 were administered orally to 15 dogs for 3 weeks, and the remaining 5 dogs served as the control."1.40Comparative evaluation of calcium-sensitizing agents, pimobendan and SCH00013, on the myocardial function of canine pacing-induced model of heart failure. ( Fukayama, T; Fukushima, R; Hamabe, L; Kawamura, K; Kim, SM; Shimizu, M; Tanaka, R; Yoshiyuki, R, 2014)
"Heart failure is associated with pathobiochemical changes that can reduce the responsiveness of the myocardium to positive inotropic agents."1.30The effect of positive inotropes on the failing human myocardium. ( Erdmann, E, 1997)
"Heart failure was induced by rapid ventricular pacing in 6 dogs instrumented with a micromanometer and a conductance catheter."1.29Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure. ( Asanoi, H; Ishise, H; Ishizaka, S; Kameyama, T; Sasayama, S, 1994)

Research

Studies (105)

TimeframeStudies, this research(%)All Research%
pre-199015 (14.29)18.7374
1990's35 (33.33)18.2507
2000's27 (25.71)29.6817
2010's24 (22.86)24.3611
2020's4 (3.81)2.80

Authors

AuthorsStudies
Erhardt, PW1
Okamoto, N1
Kubo, T2
Nakashima, Y1
Ochi, Y1
Takahashi, A2
Baba, Y1
Hirota, T1
Yamasaki, N1
Kitaoka, H1
Wess, G4
Kresken, JG3
Wendt, R1
Gaugele, J1
Killich, M1
Keller, L1
Simak, J1
Holler, P1
Bauer, A1
Küchenhof, H1
Glaus, T2
Ward, JL1
Kussin, EZ1
Tropf, MA1
Tou, SP2
DeFrancesco, TC2
Keene, BW4
Schober, KE1
Rush, JE3
Luis Fuentes, V1
Summerfield, NJ1
Wright, K1
Lehmkuhl, L1
Sayer, MP1
Loureiro, J1
MacGregor, J1
Mohren, N1
King, JN2
Hirakawa, A2
Sonobe, J1
Otaki, H1
Sakakibara, N1
Seewald, W1
Forster, S1
Boswood, A3
Gordon, SG3
Häggström, J2
Stepien, RL2
Oyama, MA3
Bonagura, J2
MacDonald, KA2
Patteson, M3
Smith, S3
Fox, PR2
Sanderson, K2
Woolley, R2
Szatmári, V2
Menaut, P2
Church, WM2
O'Sullivan, ML2
Jaudon, JP2
Rush, J2
Barrett, KA2
Rosenthal, SL2
Saunders, AB3
Ljungvall, I2
Deinert, M2
Bomassi, E2
Estrada, AH2
Fernandez Del Palacio, MJ2
Moise, NS3
Abbott, JA2
Fujii, Y2
Spier, A2
Luethy, MW2
Santilli, RA2
Uechi, M3
Tidholm, A2
Schummer, C1
Watson, P2
Beaumier, A1
Yang, VK1
Freeman, LM1
Hezzell, MJ1
Block, CL1
Laughlin, DS1
Kawano, H1
Arakawa, S1
Satoh, O1
Matsumoto, Y1
Hayano, M1
Nakatomi, D1
Yamasa, T1
Maemura, K1
Murai, K1
Seino, Y1
Kimata, N1
Inami, T1
Murakami, D1
Abe, J1
Yodogawa, K1
Maruyama, M1
Takano, M1
Ohba, T1
Ibuki, C1
Mizuno, K1
Wainberg, S1
Delk, KW1
Eshar, D1
Garcia, E1
Harkin, K1
Hamabe, L1
Kawamura, K1
Kim, SM1
Yoshiyuki, R1
Fukayama, T1
Shimizu, M1
Fukushima, R1
Tanaka, R1
Reina-Doreste, Y1
Stern, JA1
Atkins, CE1
Ames, MK1
Hodge, TE1
Meurs, KM1
Nonaka, M1
Morimoto, S1
Murayama, T1
Kurebayashi, N1
Li, L1
Wang, YY1
Arioka, M1
Yoshihara, T1
Takahashi-Yanaga, F1
Sasaguri, T1
McNaughton, A1
Frasca, S1
Mishra, N1
Tuttle, AD1
Lake-Bakaar, GA1
Singh, MK1
Kass, PH1
Griffiths, LG1
Toom, ML1
Dobak, TP1
Broens, EM1
Valtolina, C1
Mizuno, M1
Yamano, S1
Chimura, S1
Takusagawa, Y1
Sawada, T1
Maetani, S1
Mizuno, T1
Harada, K1
Shinoda, A1
Uchida, S1
Takeuchi, J1
Mizukoshi, T1
Endo, M1
Dukes-McEwan, J2
French, A1
Little, C1
Swift, S1
Willis, R1
Endoh, M2
Macgregor, JM1
Laste, NJ1
Malakoff, RL1
Cunningham, SM1
Aronow, N1
Hall, DJ1
Williams, J1
Price, LL1
Bowles, D1
Fry, D1
de Madron, E1
Strehlau, G1
White, RV1
Roland, RM1
Winter, RL1
Drourr, L1
Achen, SE1
Hariu, CD1
Fries, RC1
Boggess, MM1
Miller, MW1
Arai, M1
Caivano, D1
Birettoni, F1
Fruganti, A1
Rishniw, M1
Knafelz, P1
Porciello, F1
Boyle, KL1
Leech, E1
Sasayama, S6
Takeda, N1
Ohtaki, E1
Misu, K1
Asano, R1
Tobaru, T1
Nagayama, M1
Kitahara, K1
Umemura, J1
Sumiyoshi, T1
Hosoda, S1
Joho, S1
Asanoi, H4
Ishizaka, S2
Kameyama, T2
Inoue, H2
Kohno, M1
Matsumori, A3
Lehmann, A1
Boldt, J1
Kirchner, J1
Butson, R1
Wakaumi, M1
Shiga, T2
Naganuma, M2
Matsuda, N2
Tatami, S1
Kasanuki, H2
Watanabe, E1
Kajimoto, K1
Kawai, A1
Fuentes, VL1
Smith, PJ1
French, AT1
Van Israël, N1
Smith, SG1
Swift, ST1
Lee, AJ1
Corcoran, BM1
Schwinger, RH2
Brixius, K2
Perrone, SV1
Kaplinsky, EJ1
Hoyer, HK1
Ferasin, L1
Marcora, S1
Shinagawa, H1
Izumi, T4
Iwama, Y1
Takagi, A1
Ishise, H1
Hagemeijer, F6
Remme, WJ3
Kruijssen, DA1
van Hoogenhuyze, DC1
Krauss, XH1
Bartels, GL1
Storm, CJ1
de Leeuw, PW1
Chu, KM1
Shieh, SM1
Hu, OY1
Krayenbühl, HP1
Baumann, G4
Frick, MH1
Haehl, M1
Nehmiz, G2
Baiker, W1
Fitton, A1
Brogden, RN1
Kihara, Y1
Yokawa, S1
Terada, Y1
Yoshida, S1
Ejiri, M1
Horikoshi, I1
Kubo, SH4
Satoh, K1
Satoh, Y1
Imagawa, J1
Taira, N1
Lubsen, J1
Just, H1
Hjalmarsson, AC1
La Framboise, D1
Heinrich-Nols, J1
Dumont, JM1
Seed, P1
Ono, K1
Sato, Y1
Shioi, T1
Nose, Y1
Shiraishi, M1
Murayama, K1
Hanzawa, K1
Warabi, K1
Kamiyama, Y1
Erdmann, E1
Holubarsch, C1
Kato, K1
Ohte, N1
Cheng, CP1
Suzuki, M4
Little, WC1
Mathew, L1
Katz, SD2
Sasaki, T1
Komamura, K1
Nishikimi, T1
Matsumoto, A1
Momomura, S1
Yokoyama, I1
Aoyagi, T1
Sugiura, S1
Omata, M1
Ishiki, R1
Ishihara, T1
Izawa, H1
Nagata, K1
Hirai, M1
Yokota, M1
Yoshikawa, T1
Baba, A1
Yokozuka, H1
Okada, Y1
Nagami, K1
Takahashi, T1
Mitamura, H1
Ogawa, S1
Ako, J1
Eto, M1
Watanabe, T1
Ouchi, Y1
Chin, BS1
Lip, GY1
Tsuda, T3
Kodama, M3
Hanawa, H2
Ohshima, M1
Takahashi, M2
Aizaki, T2
Uchiyama, H2
Shibata, A3
Fujita, T1
Nonaka, R1
Miyajima, T1
Tanaka, Y1
Bergler-Klein, J2
Globits, S2
Stefenelli, T2
Mayr, H1
Porenta, G1
Sochor, H1
Glogar, D2
Rector, TS1
Cohn, JN2
Gollub, S1
Bourge, R1
Rahko, P1
Cobb, F1
Jessup, M2
Brozena, S2
Brodsky, M1
Kirlin, P1
Shanes, J1
Kuwano, H1
Pacher, R1
Troha, JM1
Wahl, J1
Sonnenblick, EH1
LeJemtel, TH1
Assmann, I1
Kassel, P1
Duck, HG1
Fiehring, H1
Morgan, P1
Schmidt, PK1
Höfs, T1
Erlemeier, HH1
Kupper, W1
Bleifeld, W1
Thierfelder, L1
Holubarsch, CH1
Hasenfuss, G1
Just, HJ1
Colucci, WS1
Wright, RF1
Braunwald, E1
Ningel, K2
Permanetter, B3
Brand, HJ3
Roth, W2
van der Giessen, WJ1
van Woerkens, LJ1
Duncker, DJ2
Roelandt, JR1
Verdouw, PD2
Pouleur, H1
Hanet, C1
Schröder, E1
Col, J1
Van Mechelen, H1
Etienne, J1
Rousseau, MF1
Hauf, GF1
Grom, E1
Jähnchen, E1
Roskamm, H1
Wirtzfeld, A1
Günes, S1
Stinshoff, M1
Klein, G1
van Mechelen, R1
van Dalen, FJ1
Hartog, JM1
Lamers, JM1
Rensen, RJ1
Saxena, PR1
Walter, M2
Liebens, I2
Goethals, H1
Renard, M2
Dresse, A2
Bernard, R2

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Tunneled Pleural Catheters for Refractory Effusions Attributed to Congestive Heart Failure (TREAT-CHF) Trial[NCT03696524]0 participants (Actual)Interventional2020-10-01Withdrawn (stopped due to Lack of enrollment)
Effects of a Multimedia Symptom Management Program on Coping Strategies, Symptom Distress, Depressive Status, and Quality of Life in Patients With Heart Failure: A Randomized Controlled Trial[NCT04715490]78 participants (Actual)Interventional2012-05-31Completed
ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial[NCT03004703]Phase 2200 participants (Actual)Interventional2017-03-16Completed
Effects of Identifying and Treating Early, Subclinical Cardiotoxicity on the Long-Term Incidence of Clinical Cardiotoxicity in Women With Breast Cancer, A Prospective Randomized Study: The Cardio-Oncology Breast Cancer Study (COBC)[NCT02571894]320 participants (Anticipated)Interventional2014-07-31Active, not recruiting
An Examination of Palliative Care as Standard Practice for Heart Failure Patients[NCT01519479]232 participants (Actual)Interventional2012-04-30Completed
Effects of a Walking Program and Inspiratory Muscle Training in Individuals With Chronic Heart Failure - A Pilot Study[NCT01560871]16 participants (Actual)Interventional2012-03-31Completed
Evaluation of the Six Minute Walk Test, Heart Rate Variability and Quality of Life in Heart Failure Patients on Beta-blocker Treatment[NCT01736137]17 participants (Actual)Observational2011-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Mean Minnesota Living With Heart Failure Questionnaire Score

This questionnaire includes 21 questions which ask how much the heart condition affected the patient's life during the past month. Each question has 5 optional answers with the scores ranging from 0 to 5. A higher score indicates a worse outcome. The minimum overall score of the questionnaire is 0 and the maximum score is 105. A higher overall score on the Minnesota Living with Heart Failure Questionnaire indicates a worse outcome. (NCT01560871)
Timeframe: Baseline and 6 weeks

,
Interventionscore on a scale (Mean)
MLHF score at baselinechange from baseline at 6 weeks
High-intensity IMT Plus Walking57.6-20.6
Low-intensity IMT Plus Walking3618.6

Change From Baseline in Mean Score of Physical Component of the SF-36 Questionnaire

The SF-36 quality of life questionnaire (short form) was used. A higher score of the SF-36 questionnaire indicates a better outcome (i.e., lower disability). The range of overall score on the SF-36 questionnaire is from 0 to 100. (NCT01560871)
Timeframe: Baseline and 6 weeks

,
Interventionscore on a scale (Mean)
Baseline Physical SF-36Change from baseline physical SF-36
High-intensity IMT Plus Walking30.77.08
Low-intensity IMT Plus Walking34.10.82

Mean Daily Step Counts From Week 1 to Week 6

Each subject was given a pedometer to record his/her step counts every day. (NCT01560871)
Timeframe: Baseline and 6 weeks

,
Interventionsteps/day (Mean)
Baseline daily step count at Week 1Daily step counts at week 6
High-intensity IMT Plus Walking70029255
Low-intensity IMT Plus Walking35124434

Respiratory Muscle Strength is Indicated by Maximal Inspiratory Pressure (PImax)

The inspiratory muscle strength will be measured in the unit of cmH2O by the Respiratory Muscle Pressure Meter (Micro Direct). A higher inspiratory pressure indicates a better inspiratory breathing strength. (NCT01560871)
Timeframe: Baseline and 6 weeks

,
Interventioncm H2O (Mean)
Baseline PImax at week 1PImax at week 6
High-intensity IMT Plus Walking43.5358.13
Low-intensity IMT Plus Walking51.4457.22

Six-minute Walk Test Distance

The six-minute walk test is a measure of cardiovascular endurance which measures how far a person can walk in 6 minutes. This test was conducted twice respectively at pre-training and at post-training to account for potential learning effect. A longer distance walked on the six-minute walking test indicates a better cardiovascular endurance. (NCT01560871)
Timeframe: Baseline and 6 Weeks

,
Interventionmeters (Mean)
six-minute walk distance at week 1Six-minute walk distance at week 6
High-intensity IMT Plus Walking378.04419.71
Low-intensity IMT Plus Walking356.16375.78

Reviews

25 reviews available for pimobendan and Heart Failure

ArticleYear
In search of the digitalis replacement.
    Journal of medicinal chemistry, 1987, Volume: 30, Issue:2

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiotonic Agents; Cyclic AMP; Digitalis Glycosides; Heart Fai

1987
Cardiac Ca2+ signaling and Ca2+ sensitizers.
    Circulation journal : official journal of the Japanese Circulation Society, 2008, Volume: 72, Issue:12

    Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Angiotensin II; Animals; Azocines; Calcium; Cal

2008
Pimobendan and its use in treating canine congestive heart failure.
    Compendium (Yardley, PA), 2011, Volume: 33, Issue:11

    Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Heart Failure; Pyridazines; Treatment Outcome

2011
[Calcium mobilizers and calcium sensitizers].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 9

    Topics: Calcium; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Pyridazines;

2011
A review of the pharmacology and clinical uses of pimobendan.
    Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001), 2012, Volume: 22, Issue:4

    Topics: Animals; Cardiotonic Agents; Heart Failure; Pyridazines

2012
[Pharmacological treatment of heart failure].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 4

    Topics: Acute Disease; Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotensi

2003
[Roles of cytokines in the pathogenesis of heart failure].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Cytokines; Disease Models, Animal; Genetic Therapy; Heart Failure;

2003
[Inotropic agents].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:5

    Topics: Adrenergic alpha-Agonists; Animals; Cardiotonic Agents; Clinical Trials as Topic; Digitalis Glycosid

2003
The role of Ca++-sensitizers for the treatment of heart failure.
    Current opinion in critical care, 2003, Volume: 9, Issue:5

    Topics: Calcium; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Dobutamine; Heart Failure; H

2003
Use of pimobendan in the management of heart failure.
    The Veterinary clinics of North America. Small animal practice, 2004, Volume: 34, Issue:5

    Topics: Animals; Cardiotonic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Heart Failure; Phosphodiesteras

2004
[Cytokine antagonists and endothelin antagonists for therapy of heart failure].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2005, Feb-10, Volume: 94, Issue:2

    Topics: Angiotensin II; Animals; Antibodies, Monoclonal; Bosentan; Clinical Trials as Topic; Cytokines; Endo

2005
[If the myofilaments become sensitive: Ca2+-sensitizer for the therapy of heart insufficiency].
    Deutsche medizinische Wochenschrift (1946), 2005, Apr-15, Volume: 130, Issue:15

    Topics: Actin Cytoskeleton; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydrazones; Myocardiu

2005
Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
    International journal of cardiology, 2005, Sep-01, Volume: 103, Issue:3

    Topics: Arrhythmias, Cardiac; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan

2005
Ca2+-sensitisers--a promising option to treat heart failure?
    Cardiovascular drugs and therapy, 2005, Volume: 19, Issue:6

    Topics: Calcium; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan

2005
[Calcium sensitizer: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, May-28, Volume: 65 Suppl 5

    Topics: Calcium; Cardiotonic Agents; Clinical Trials as Topic; Contraindications; Heart Failure; Humans; Hyd

2007
[Calcium sensitizer agents in heart failure therapy].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, May-28, Volume: 65 Suppl 5

    Topics: Calcium; Cardiotonic Agents; Clinical Trials as Topic; Heart Failure; Humans; Hydrazones; Myocardial

2007
Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
    Drugs & aging, 1994, Volume: 4, Issue:5

    Topics: Administration, Oral; Animals; Cardiotonic Agents; Clinical Trials as Topic; Drug Interactions; Elec

1994
Inotropic agents with calcium-sensitizing properties: clinical and hemodynamic effects of pimobendan.
    Coronary artery disease, 1994, Volume: 5, Issue:2

    Topics: Animals; Calcium; Cardiotonic Agents; Clinical Trials as Topic; Heart Failure; Hemodynamics; Humans;

1994
Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure.
    European heart journal, 1993, Volume: 14, Issue:4

    Topics: Animals; Calcium; Death, Sudden, Cardiac; Heart Failure; Hemodynamics; Humans; Myocardial Contractio

1993
Inotropic agents in the treatment of heart failure: despair or hope?
    Cardiovascular drugs and therapy, 1997, Volume: 10, Issue:6

    Topics: Adrenergic beta-Agonists; Cardiotonic Agents; Cyclic AMP; Digitalis; Heart Failure; Humans; Plants,

1997
Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure.
    Cardiology, 1997, Volume: 88 Suppl 2

    Topics: Cardiotonic Agents; Exercise Tolerance; Heart Failure; Humans; Pyridazines; Quality of Life; Randomi

1997
Calcium sensitising agents in heart failure.
    Drugs & aging, 1998, Volume: 12, Issue:3

    Topics: Aged; Animals; Calcium; Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Pyridazines; Simendan

1998
[Ca2+ sensitizers].
    Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 2000, Volume: 45, Issue:6 Suppl

    Topics: Animals; Calcium; Cardiotonic Agents; Cyclic AMP; Dihydropyridines; Drug Design; Heart Failure; Huma

2000
New pharmacological strategies for the treatment of heart failure.
    Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:7

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atrial Natriuretic Factor; Bosentan; Calcium;

2001
New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.
    The New England journal of medicine, 1986, Feb-06, Volume: 314, Issue:6

    Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e

1986

Trials

32 trials available for pimobendan and Heart Failure

ArticleYear
Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
    Journal of veterinary internal medicine, 2020, Volume: 34, Issue:6

    Topics: Animals; Dog Diseases; Dogs; Furosemide; Heart Failure; Mitral Valve; Prospective Studies; Pyridazin

2020
Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study.
    Journal of veterinary internal medicine, 2021, Volume: 35, Issue:2

    Topics: Animals; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cat Diseases; Cats; Dog Diseases; Dogs; H

2021
Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.
    Journal of veterinary science, 2018, Jan-31, Volume: 19, Issue:1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Dog Diseases; Dogs; Drug Combinatio

2018
Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
    Journal of veterinary internal medicine, 2018, Volume: 32, Issue:1

    Topics: Animals; Cardiomegaly; Cardiotonic Agents; Dog Diseases; Dogs; Echocardiography; Heart Diseases; Hea

2018
Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Journal of veterinary internal medicine, 2018, Volume: 32, Issue:5

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Diuretics; Dog Diseases; Dogs

2018
Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
    Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 2015, Volume: 17, Issue:2

    Topics: Animals; Arrhythmias, Cardiac; Breeding; Cardiotonic Agents; Dog Diseases; Dogs; Double-Blind Method

2015
Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Journal of veterinary internal medicine, 2016, Volume: 30, Issue:6

    Topics: Animals; Cardiomegaly; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Failure; Male; Mitral V

2016
Plasma concentration profile of orally administered pimobendan and plasma brain natriuretic peptide level in patients with severe heart failure.
    Cardiovascular drugs and therapy, 2003, Volume: 17, Issue:3

    Topics: Administration, Oral; Cardiomyopathy, Dilated; Cardiotonic Agents; Heart Failure; Humans; Natriureti

2003
Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
    The Journal of small animal practice, 2005, Volume: 46, Issue:3

    Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Electrocardiography; Heart Failure; Mitral Valve; M

2005
Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
    Journal of cardiovascular pharmacology, 1994, Volume: 24, Issue:5

    Topics: Adult; Aged; Blood Pressure; Cardiac Output; Cardiotonic Agents; Catecholamines; Coronary Angiograph

1994
Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group.
    European heart journal, 1994, Volume: 15, Issue:7

    Topics: Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography, Ambulatory; Enalapril; E

1994
Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure.
    Heart and vessels, 1994, Volume: 9, Issue:3

    Topics: Activities of Daily Living; Cardiotonic Agents; Chronic Disease; Dose-Response Relationship, Drug; D

1994
Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.
    Heart (British Cardiac Society), 1996, Volume: 76, Issue:3

    Topics: Aged; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Exerci

1996
Clinical efficacy and safety of pimobendan in treatment of heart failure--experience in Japan.
    Cardiology, 1997, Volume: 88 Suppl 2

    Topics: Administration, Oral; Cardiotonic Agents; Double-Blind Method; Heart Failure; Hemodynamics; Humans;

1997
Effects of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure.
    Journal of cardiology, 1999, Volume: 33, Issue:6

    Topics: Adult; Aged; Atrial Natriuretic Factor; Drug Therapy, Combination; Female; Heart Failure; Humans; Ma

1999
Pimobendan has a potent venodilating action in patients with congestive heart failure.
    Cardiovascular drugs and therapy, 1998, Volume: 12, Issue:6

    Topics: Cardiotonic Agents; Heart Failure; Humans; Male; Middle Aged; Pyridazines; Regional Blood Flow; Vaso

1998
Acute effects of a single low oral dose of pimobendan on left ventricular systolic and diastolic function in patients with congestive heart failure.
    Journal of cardiovascular pharmacology, 2000, Volume: 35, Issue:6

    Topics: Administration, Oral; Adult; Cardiotonic Agents; Diastole; Dose-Response Relationship, Drug; Heart F

2000
Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group.
    The American journal of cardiology, 2000, Jun-15, Volume: 85, Issue:12

    Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiotonic Agents; Carvedilol; Drug Therapy, Combination;

2000
Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study).
    Circulation journal : official journal of the Japanese Circulation Society, 2002, Volume: 66, Issue:2

    Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiotonic Agents

2002
[Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure].
    Zeitschrift fur Kardiologie, 1992, Volume: 81, Issue:10

    Topics: Cardiac Volume; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Echocardiography; Electroc

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group.
    American heart journal, 1992, Volume: 124, Issue:4

    Topics: Activities of Daily Living; Attitude to Health; Double-Blind Method; Female; Follow-Up Studies; Hear

1992
Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.
    Circulation, 1992, Volume: 85, Issue:3

    Topics: Analysis of Variance; Cardiotonic Agents; Double-Blind Method; Exercise Test; Female; Heart Failure;

1992
Acute hemodynamics of pimobendan in chronic heart failure. A comparative crossover study of captopril and pimobendan.
    Japanese heart journal, 1992, Volume: 33, Issue:2

    Topics: Aged; Captopril; Cardiotonic Agents; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged;

1992
A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
    American heart journal, 1992, Volume: 123, Issue:1

    Topics: Cardiotonic Agents; Chronic Disease; Double-Blind Method; Exercise Test; Female; Heart Failure; Hemo

1992
[Acute and long-term effects of pimobendan (UD-CG 115) in NYHA II and III heart failure. Results of a randomized multicenter double-blind study].
    Zeitschrift fur Kardiologie, 1991, Volume: 80, Issue:11

    Topics: Adult; Aged; Cardiac Glycosides; Cardiotonic Agents; Diuretics; Double-Blind Method; Drug Therapy, C

1991
Intractable heart failure despite angiotensin-converting enzyme inhibitors, digoxin, and diuretics: long-term effectiveness of add-on therapy with pimobendan.
    American heart journal, 1991, Volume: 122, Issue:2

    Topics: Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Digoxin; Diuretics

1991
Comparison of hormonal and haemodynamic changes after long-term oral therapy with pimobendan or enalapril--a double-blind randomized study.
    European heart journal, 1991, Volume: 12, Issue:8

    Topics: Aged; Body Weight; Creatinine; Double-Blind Method; Enalapril; Exercise Test; Female; Heart Failure;

1991
Cardiovascular profile of UDCG 115 BS-pimobendane and reversibility of catecholamine subsensitivity in severe congestive heart failure secondary to idiopathic dilated cardiomyopathy.
    Journal of cardiovascular pharmacology, 1989, Volume: 13, Issue:5

    Topics: Blood Pressure; Cardiac Output; Cardiomyopathy, Dilated; Catecholamines; Dobutamine; Heart Failure;

1989
Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure.
    Journal of cardiovascular pharmacology, 1989, Volume: 14 Suppl 2

    Topics: Adult; Blood Pressure; Cardiac Output; Cardiomyopathy, Dilated; Cardiotonic Agents; Chronic Disease;

1989
Acute and long-term hemodynamic effects of pimobendan (UD-CG 115 BS) in comparison with captopril.
    Journal of cardiovascular pharmacology, 1989, Volume: 14 Suppl 2

    Topics: Adult; Captopril; Cardiotonic Agents; Chronic Disease; Exercise; Female; Heart Failure; Heart Rate;

1989
[Acute and chronic effects of UDCG 115 BS (pimobendan) in patients with advanced myocardial failure].
    Zeitschrift fur Kardiologie, 1989, Volume: 78, Issue:5

    Topics: Adult; Aged; Cardiac Output; Cardiomyopathy, Dilated; Cardiotonic Agents; Clinical Trials as Topic;

1989
Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic cross-over and double-blind study with two different doses.
    British journal of clinical pharmacology, 1988, Volume: 25, Issue:3

    Topics: Aged; Cardiac Output; Cardiotonic Agents; Clinical Trials as Topic; Double-Blind Method; Heart Failu

1988

Other Studies

48 other studies available for pimobendan and Heart Failure

ArticleYear
Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis.
    Internal medicine (Tokyo, Japan), 2020, Feb-01, Volume: 59, Issue:3

    Topics: Aged; Aged, 80 and over; Amyloid; Amyloid Neuropathies, Familial; Cardiotonic Agents; Female; Heart

2020
Retrospective evaluation of the safety and tolerability of pimobendan in cats with obstructive vs nonobstructive cardiomyopathy.
    Journal of veterinary internal medicine, 2020, Volume: 34, Issue:6

    Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Cat Diseases; Cats; Heart Failure; Pyridazines; Retro

2020
Clinical findings and survival time in dogs with advanced heart failure.
    Journal of veterinary internal medicine, 2018, Volume: 32, Issue:3

    Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Female; Furosemide; Heart Failure; Male; Mitral Val

2018
What Is Your Diagnosis?
    Journal of avian medicine and surgery, 2018, Volume: 32, Issue:1

    Topics: Animals; Atherosclerosis; Bird Diseases; Cardiotonic Agents; Diagnosis, Differential; Diuretics; Ech

2018
Effect of pimobendan in addition to standard therapy for heart failure on prevention of readmission in elderly patients with severe chronic heart failure.
    Geriatrics & gerontology international, 2014, Volume: 14, Issue:1

    Topics: Aged; Aged, 80 and over; Biomarkers; Cardiotonic Agents; Disease Progression; Dose-Response Relation

2014
Efficacy and limitations of oral inotropic agents for the treatment of chronic heart failure.
    International heart journal, 2013, Volume: 54, Issue:2

    Topics: Administration, Oral; Aged; Aged, 80 and over; Cardiotonic Agents; Chronic Disease; Cross-Sectional

2013
Use of pimobendan in feline congenital heart failure.
    The Canadian veterinary journal = La revue veterinaire canadienne, 2013, Volume: 54, Issue:12

    Topics: Animals; Cardiotonic Agents; Cat Diseases; Cats; Female; Heart Failure; Pyridazines; Tricuspid Valve

2013
Diagnosis and treatment of congestive heart failure secondary to dilated cardiomyopathy in a hedgehog.
    The Journal of small animal practice, 2014, Volume: 55, Issue:3

    Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Carnitine; Drug Therapy, Combination; Heart Fa

2014
Comparative evaluation of calcium-sensitizing agents, pimobendan and SCH00013, on the myocardial function of canine pacing-induced model of heart failure.
    Journal of pharmacological sciences, 2014, Volume: 124, Issue:3

    Topics: Administration, Oral; Animals; Calcium; Cardiotonic Agents; Dihydropyridines; Dilatation, Pathologic

2014
Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure.
    Journal of the American Veterinary Medical Association, 2014, Sep-01, Volume: 245, Issue:5

    Topics: Animals; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Case-Control Studies; Cat Diseases; Cats;

2014
Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure.
    British journal of pharmacology, 2015, Volume: 172, Issue:9

    Topics: Animals; Calcium Channels, L-Type; Calcium Signaling; Cardiomyopathy, Dilated; Cardiotonic Agents; D

2015
Valvular dysplasia and congestive heart failure in a juvenile African penguin (Spheniscus demersus).
    Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians, 2014, Volume: 45, Issue:4

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Zoo; Bird Diseases; Cardiotonic Agents;

2014
Interstitial pneumonia and pulmonary hypertension associated with suspected ehrlichiosis in a dog.
    Acta veterinaria Scandinavica, 2016, Jul-07, Volume: 58, Issue:1

    Topics: Animals; Antiparasitic Agents; Dog Diseases; Dogs; Doxycycline; Ehrlichiosis; Heart Failure; Hyperte

2016
Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.
    The Journal of veterinary medical science, 2017, Jan-20, Volume: 79, Issue:1

    Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Failure; Male; Mitral Valve Insuffici

2017
Treatment of congestive heart failure in dogs.
    The Veterinary record, 2008, Oct-25, Volume: 163, Issue:17

    Topics: Animals; Cardiotonic Agents; Dog Diseases; Dogs; Heart Failure; Pyridazines; Randomized Controlled T

2008
Use of pimobendan in 170 cats (2006-2010).
    Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 2011, Volume: 13, Issue:4

    Topics: Animals; Cardiotonic Agents; Cat Diseases; Cats; Dose-Response Relationship, Drug; Female; Follow-Up

2011
Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.
    The Canadian veterinary journal = La revue veterinaire canadienne, 2011, Volume: 52, Issue:11

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cardiotonic Agents; Death, Sudden,

2011
Effect of oral administration of pimobendan in cats with heart failure.
    Journal of the American Veterinary Medical Association, 2012, Jul-01, Volume: 241, Issue:1

    Topics: Administration, Oral; Animals; Cardiotonic Agents; Cat Diseases; Cats; Cohort Studies; Female; Heart

2012
Transthoracic echocardiographically-guided interventional cardiac procedures in the dog.
    Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 2012, Volume: 14, Issue:3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Balloon Valvuloplasty; Benzazepines; Cardiotonic

2012
Inotropic agents and immune modulation.
    Cardiovascular drugs and therapy, 2002, Volume: 16, Issue:3

    Topics: Adjuvants, Immunologic; Animals; Cardiotonic Agents; Clinical Trials as Topic; Cytokines; Heart Fail

2002
Normalization of left ventricular parameters following combined pimobendan and carvedilol treatment in a case of unclassified cardiomyopathy with longstanding refractory status.
    Internal medicine (Tokyo, Japan), 2002, Volume: 41, Issue:12

    Topics: Carbazoles; Cardiomyopathies; Cardiovascular Agents; Carvedilol; Heart Failure; Humans; Male; Middle

2002
Disparate force-frequency effects of pimobendan and dobutamine in conscious dogs with tachycardia-induced cardiomyopathy.
    Journal of cardiac failure, 2002, Volume: 8, Issue:6

    Topics: Adrenergic beta-Agonists; Animals; Cardiac Pacing, Artificial; Cardiotonic Agents; Dobutamine; Dogs;

2002
Treatment of congestive heart failure.
    The Journal of small animal practice, 2003, Volume: 44, Issue:11

    Topics: Animals; Cardiotonic Agents; Data Interpretation, Statistical; Dog Diseases; Dogs; Heart Failure; Py

2003
Low-dose systemic phosphodiesterase III inhibitor pimobendan combined with prostacyclin therapy in a patient with severe primary pulmonary hypertension.
    Cardiovascular drugs and therapy, 2003, Volume: 17, Issue:4

    Topics: Adult; Drug Therapy, Combination; Epoprostenol; Female; Heart Failure; Humans; Hypertension, Pulmona

2003
A pilot study to assess the feasibility of a submaximal exercise test to measure individual response to cardiac medication in dogs with acquired heart failure.
    Veterinary research communications, 2007, Volume: 31, Issue:6

    Topics: Animals; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Cardiotonic Agents; Dog Disease

2007
Disparate inotropic and lusitropic responses to pimobendan in conscious dogs with tachycardia-induced heart failure.
    Journal of cardiovascular pharmacology, 1994, Volume: 23, Issue:2

    Topics: Animals; Cardiac Catheterization; Cardiotonic Agents; Diastole; Dogs; Electric Stimulation; Electrop

1994
Hemodynamic performance during exercise in patients with severe chronic congestive heart failure before and after a single dose of pimobendan.
    Journal of cardiovascular pharmacology, 1994, Volume: 23, Issue:5

    Topics: Administration, Oral; Aged; Cardiomyopathy, Dilated; Cardiotonic Agents; Child; Exercise; Female; He

1994
Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
    Clinical pharmacology and therapeutics, 1995, Volume: 57, Issue:6

    Topics: Administration, Oral; Analysis of Variance; Cardiomyopathy, Dilated; Cardiotonic Agents; Echocardiog

1995
Improvement of cardiac performance by pimobendan, a new cardiotonic drug, in the experimental failing dog heart.
    Japanese heart journal, 1993, Volume: 34, Issue:2

    Topics: Animals; Cardiotonic Agents; Dogs; Dose-Response Relationship, Drug; Female; Heart; Heart Failure; M

1993
Positive inotropic agents: a double-edged sword for chronic heart failure.
    Internal medicine (Tokyo, Japan), 1996, Volume: 35, Issue:1

    Topics: Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Hea

1996
Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Journal of molecular and cellular cardiology, 1996, Volume: 28, Issue:12

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzy

1996
[Epidural anesthesia for herniorrhaphy in a patient with severe dilated cardiomyopathy (DCM) under pimobendan control].
    Masui. The Japanese journal of anesthesiology, 1997, Volume: 46, Issue:1

    Topics: Anesthesia, Epidural; Cardiomyopathy, Dilated; Cardiotonic Agents; Dobutamine; Dopamine; Fentanyl; H

1997
The effect of positive inotropes on the failing human myocardium.
    Cardiology, 1997, Volume: 88 Suppl 2

    Topics: 1-Methyl-3-isobutylxanthine; Adrenergic beta-Agonists; Calcium; Cardiotonic Agents; Dobutamine; Hear

1997
New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors.
    Cardiology, 1997, Volume: 88 Suppl 2

    Topics: Animals; Calcium; Cardiotonic Agents; Deoxyepinephrine; Energy Metabolism; Guinea Pigs; Heart Failur

1997
The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure.
    The Journal of pharmacology and experimental therapeutics, 1997, Volume: 282, Issue:1

    Topics: Amrinone; Animals; Dogs; Heart Failure; Phosphodiesterase Inhibitors; Physical Conditioning, Animal;

1997
A case of severe hypoglycemia due to pimobendan.
    International journal of cardiology, 2001, Volume: 80, Issue:1

    Topics: Aged; Cardiotonic Agents; Heart Failure; Humans; Hypoglycemia; Male; Pyridazines

2001
[Acute hemodynamic effects of pimobendan and captopril: a comparative study in the same patients with chronic heart failure].
    Journal of cardiology, 1992, Volume: 22, Issue:4

    Topics: Aged; Captopril; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pyridazines; Vasodi

1992
[A case of dilated cardiomyopathy with intractable heart failure treated with adjunctive therapy of pimobendan and denopamine].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1992, Jul-10, Volume: 81, Issue:7

    Topics: Cardiomyopathy, Dilated; Chemotherapy, Adjuvant; Ethanolamines; Furosemide; Heart Failure; Humans; I

1992
Heart rate behaviour at different stages of congestive heart failure.
    European heart journal, 1992, Volume: 13, Issue:7

    Topics: Adult; Aged; Cardiotonic Agents; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate;

1992
Myocardial energetics in dilated cardiomyopathy.
    Clinical cardiology, 1990, Volume: 13, Issue:9

    Topics: Adrenergic beta-Agonists; Cardiac Output; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Circ

1990
Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing.
    Journal of cardiovascular pharmacology, 1989, Volume: 14, Issue:2

    Topics: Aged; Blood Chemical Analysis; Blood Pressure; Cardiac Output; Cardiotonic Agents; Exercise Test; Fe

1989
Acute hemodynamic effects of nisoldipine and pimobendan in conscious pigs with chronic heart failure.
    Journal of cardiovascular pharmacology, 1989, Volume: 14, Issue:4

    Topics: Acid-Base Equilibrium; Animals; Blood Gas Analysis; Chronic Disease; Heart Failure; Hemodynamics; Ni

1989
Pharmacotherapy of congestive heart failure: pimobendan, a new approach to inotropic stimulation. Proceedings of a satellite symposium to the Xth European Congress of Cardiology. Vienna, Austria, August 31, 1988.
    Journal of cardiovascular pharmacology, 1989, Volume: 14 Suppl 2

    Topics: Animals; Cardiotonic Agents; Heart Failure; Humans; Pyridazines

1989
Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure.
    Journal of cardiovascular pharmacology, 1989, Volume: 14 Suppl 2

    Topics: Animals; Cardiac Output, Low; Cardiotonic Agents; Dogs; Heart Failure; Heart Ventricles; Hemodynamic

1989
Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure.
    Journal of cardiovascular pharmacology, 1989, Volume: 14 Suppl 2

    Topics: Administration, Oral; Aged; Cardiotonic Agents; Cardiovascular System; Female; Heart Failure; Hemody

1989
Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    The American journal of cardiology, 1989, Mar-01, Volume: 63, Issue:9

    Topics: Administration, Oral; Aged; Cardiomyopathy, Dilated; Coronary Disease; Female; Heart Failure; Hemody

1989
Usefulness of pimobendan in the treatment of heart failure.
    Arzneimittel-Forschung, 1986, Volume: 36, Issue:12

    Topics: Animals; Cardiac Output; Cardiotonic Agents; Cyclic AMP; Cyclic GMP; Heart Failure; Myocardial Contr

1986
Pimobendane (UD-CG 115 BS) in chronic congestive heart failure. Short-term and one-month effects of a new inotropic vasodilating agent.
    Chest, 1988, Volume: 93, Issue:6

    Topics: Administration, Oral; Aged; Cardiotonic Agents; Chromatography, High Pressure Liquid; Epinephrine; F

1988